Extended Data Fig. 3: Alternative ex vivo labelling of CAR T-cells with [89Zr]Zr-Oxine and PSMA imaging with [86Y]Y-DOTA-PSMA. | Nature Biomedical Engineering

Extended Data Fig. 3: Alternative ex vivo labelling of CAR T-cells with [89Zr]Zr-Oxine and PSMA imaging with [86Y]Y-DOTA-PSMA.

From: Simultaneous quantitative imaging of two PET radiotracers via the detection of positron–electron annihilation and prompt gamma emissions

Extended Data Fig. 3: Alternative ex vivo labelling of CAR T-cells with [89Zr]Zr-Oxine and PSMA imaging with [86Y]Y-DOTA-PSMA.The alternative text for this image may have been generated using AI.

[86Y]Y-DOTA-PSMA / [89Zr]Zr-oxine CAR T-cell mPET was found to have uptake of both PSMA-11 and CAR T -cell tracers in the PSMA-positive tumour (left), whereas minor to no activity was observed in both tracers for the PSMA-null tumour (right). Distribution of the [86Y]Y-DOTA-PSMA tracer can be seen in the PSMA-positive tumour, in the ocular cavity where injected, and in the bladder during excretion. [89Zr]Zr-oxine CAR T-cells were observed in the PSMA-positive tumour as well as in the liver and bone. Images were calibrated to a maximal 2.5 %IA/CC for [86Y]Y-DOTA-PSMA and 7.5 %IA/CC for [89Zr]Zr-oxine CAR T-cells. We used one mouse. %IA/CC represents percent injected activity per cubic centimetre.

Back to article page